Kura Oncology, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $40.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors related to Kura Oncology’s promising clinical trial results and strategic advancements. The ongoing Phase 3 KOMET-017 trials are pivotal, as they continue to demonstrate the potential of ziftomenib in combination with standard of care (SoC) treatments for acute myeloid leukemia (AML). The data from the KOMET-007 trial, presented at ASH ’25, highlighted robust activity in both newly diagnosed and relapsed/refractory AML patients, reinforcing the efficacy and safety profile of ziftomenib.
Furthermore, the combination of ziftomenib with venetoclax and azacitidine has shown to be well-tolerated, without increasing toxicity beyond expected levels. This supports the advancement of ziftomenib in the challenging frontline AML population. The strategic collaborations and recent approvals for ziftomenib in specific AML subtypes also contribute to the positive outlook for Kura Oncology, underpinning Pantginis’s confidence in the company’s growth potential and the Buy rating.
In another report released today, Barclays also maintained a Buy rating on the stock with a $28.00 price target.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KURA in relation to earlier this year.